Close
Close

Lassa Lineage II Virus-like Particles (LASV II VLPs) (CAT#: VLP-029YF)

Datasheet
Recombinant Lassa Lineage II Virus-like Particles (LASV II VLPs) are produced in mammalian HEK293 cells, assembled with Z, GPC and NP antigens. VLP is mimicking the native 3D structure of viruses which can elicit strong immune responses. However, VLPs lack viral genomic material which makes them non-infectious, unable to replicate and enhance the safety during manufacture and administration. LASV II VLPs can be used in the development of LASV II diagnostics and in vaccine development and R&D (including use as an immunogen).

Product Specifications

  • Structural Proteins
  • Z, GPC and NP proteins
  • Expression Systems
  • HEK293 expression system
  • Buffer
  • Tris NaCl containing EDTA, glycerol, arginine and glutamic acid
  • Form
  • Liquid
  • Alternative Names
  • Lassa Lineage II virus-like particles; LASV II VLPs; Lassa Lineage II virus; LASV II virus-like particles; VLPs; Virus-like Particles
  • Storage
  • Store at 4°C short term (2-4 weeks). Store at -80 °C long term. Avoid repeated freeze/thaw cycles.

Virus Background

  • Virus Family
  • Arenaviridae
  • Virus Species
  • Lassa Virus Lineage II
  • Virus Overview
  • Lassa virus, an Old World arenavirus (family Arenaviridae), is the etiological agent of Lassa fever, a severe human disease that is reported in more than 100,000 patients annually in the endemic regions of West Africa with mortality rates for hospitalized patients varying between 5-10%. Lassa virus causes Lassa fever, a hemorrhagic disease characterized by fever, generalized weakness, muscle pain, nausea and vomiting with mucosal bleeding. Arenaviruses have pleomorphic virions from 40 to more than 200 nm in diameter that consist of nucleocapsid surrounded by a lipid envelope.
  • Virus Structure
  • Enveloped, single-stranded, and bi-segmented RNA virus
  • Related Disease
  • Lassa hemorrhagic fever

Customer reviews and Q&As    

Customer Review

Induction of immune response

The Natal multimammate rat developed a severe immune response after LASV II VLP inoculation.
2022-12-28

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

Related Products
Online Inquiry
CONTACT US
USA:
Europe:
Germany:
Call us at:
USA:
UK:
Germany:
Fax:
Email:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us
© 2024 Creative Biolabs. | Contact Us